421 institutions reported holding ARWR for 2026Q1, together 85% of the company, more than the 392 a quarter earlier. Institutions reporting a position: 421 (as of 2026Q1). Shares held by institutions: 120.7M, long US equity positions only, as reported on Form 13F. Reported value: $7.57B, at 2026-03-31 prices, not today's. Top 5 holders: 40%, of the whole company, between five filers.

ARWRArrowhead Pharmaceuticals, Inc.

HealthcareUSD

$89.07

$16.4252 weeks$89.61

Who owns ARWR

421 institutions reported holding ARWR for 2026Q1, together 85% of the company, more than the 392 a quarter earlier.

421

Institutions reporting a position · as of 2026Q1 · up from 392 the quarter before

Shares held by institutions: 120.7M
Shares held by institutions · 85% of the company · long US equity positions only, as reported on Form 13F
Reported value: $7.57B
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 40%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 52
New positions: 92
Positions exited: 69
Added to: 154
Reduced: 105
Top 10 holdersof the company: 51%

Institutional ownership by quarter, 2013Q2 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	421	120.7M	$7.57B
2025Q4	392	115.8M	$7.69B
2025Q3	300	110.8M	$3.82B
2025Q2	280	105.8M	$1.67B
2025Q1	262	105.3M	$1.34B
2024Q4	267	99.7M	$1.87B
2024Q3	269	97.8M	$1.90B
2024Q2	270	97.7M	$2.54B
2024Q1	271	96.7M	$2.77B
2023Q4	263	77.5M	$2.37B
2023Q3	252	74.6M	$2.01B
2023Q2	270	72.3M	$2.57B
2023Q1	253	72.9M	$1.85B
2022Q4	279	73.2M	$2.97B
2022Q3	274	71.0M	$2.35B
2022Q2	275	72.2M	$2.54B

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
BlackRock Inc.	18.2M	13%	$1.14B
VANGUARD GROUP INC	14.4M	10%	$901M
Avoro Capital Advisors LLC	10.7M	7.5%	$671M
FMR LLC	7.3M	5.1%	$456M
STATE STREET CORP	6.5M	4.6%	$407M
GEODE CAPITAL MANAGEMENT LLC	4.3M	3.0%	$275M
FRED ALGER MANAGEMENT, LLC	3.3M	2.3%	$210M
Invesco Ltd.	3.3M	2.3%	$206M
Vestal Point Capital, LP	2.3M	1.6%	$143M
BAKER BROS. ADVISORS LP	2.0M	1.4%	$125M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Biotechnology

Ranks #78 of 145 by Smart Score

Compare peers

BMRN+0.03%

BioMarin Pharmaceutical Inc.

SMMT-0.49%

Summit Therapeutics Inc.

CYTK-0.49%

Cytokinetics, Incorporated

KRYS+3.5%

Krystal Biotech, Inc.

MDGL+0.79%

Madrigal Pharmaceuticals, Inc.

AXSM-0.25%

Axsome Therapeutics, Inc.